Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Piñol V, Xicola RM, Bujanda L, Reñé JM, Clofent J, Bessa X, Morillas JD, Nicolás-Pérez D, Payá A, Alenda C; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Jover R, et al. Among authors: paya a. Gut. 2006 Jun;55(6):848-55. doi: 10.1136/gut.2005.073015. Epub 2005 Nov 18. Gut. 2006. PMID: 16299036 Free PMC article.
Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency.
Castells A, Payá A, Alenda C, Rodríguez-Moranta F, Agrelo R, Andreu M, Piñol V, Castellví-Bel S, Jover R, Llor X, Pons E, Elizalde JI, Bessa X, Alcedo J, Saló J, Medina E, Naranjo A, Esteller M, Piqué JM; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Castells A, et al. Among authors: paya a. Clin Cancer Res. 2006 Mar 15;12(6):1686-92. doi: 10.1158/1078-0432.CCR-05-1581. Clin Cancer Res. 2006. PMID: 16551850
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Balaguer F, Sempere L, Xicola RM, Bujanda L, Reñé JM, Clofent J, Bessa X, Morillas JD, Nicolás-Pérez D, Pons E, Payá A, Alenda C; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Jover R, et al. Among authors: paya a. Eur J Cancer. 2009 Feb;45(3):365-73. doi: 10.1016/j.ejca.2008.07.016. Epub 2008 Aug 21. Eur J Cancer. 2009. PMID: 18722765
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
Jover R, Nguyen TP, Pérez-Carbonell L, Zapater P, Payá A, Alenda C, Rojas E, Cubiella J, Balaguer F, Morillas JD, Clofent J, Bujanda L, Reñé JM, Bessa X, Xicola RM, Nicolás-Pérez D, Castells A, Andreu M, Llor X, Boland CR, Goel A. Jover R, et al. Among authors: paya a. Gastroenterology. 2011 Apr;140(4):1174-81. doi: 10.1053/j.gastro.2010.12.035. Epub 2010 Dec 24. Gastroenterology. 2011. PMID: 21185836 Free PMC article.
Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C, Alenda C, Payá A, Brea A, Egoavil CM, Castillejo A, Barberá VM, Bessa X, Xicola RM, Rodríguez-Soler M, Sánchez-Fortún C, Acame N, Castellví-Bel S, Piñol V, Balaguer F, Bujanda L, De-Castro ML, Llor X, Andreu M, Carracedo A, Soto JL, Castells A, Jover R. Pérez-Carbonell L, et al. Among authors: paya a. Gut. 2012 Jun;61(6):865-72. doi: 10.1136/gutjnl-2011-300041. Epub 2011 Aug 25. Gut. 2012. PMID: 21868491
Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.
Piñol V, Castells A, Andreu M, Castellví-Bel S, Alenda C, Llor X, Xicola RM, Rodríguez-Moranta F, Payá A, Jover R, Bessa X; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Piñol V, et al. Among authors: paya a. JAMA. 2005 Apr 27;293(16):1986-94. doi: 10.1001/jama.293.16.1986. JAMA. 2005. PMID: 15855432
Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway.
Llor X, Pons E, Xicola RM, Castells A, Alenda C, Piñol V, Andreu M, Castellví-Bel S, Payá A, Jover R, Bessa X, Girós A, Roca A, Gassull MA; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Llor X, et al. Among authors: paya a. Clin Cancer Res. 2005 Oct 15;11(20):7304-10. doi: 10.1158/1078-0432.CCR-05-0965. Clin Cancer Res. 2005. PMID: 16243801
Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: proposal of a new and simpler set of recommendations.
Rodríguez-Moranta F, Castells A, Andreu M, Piñol V, Castellví-Bel S, Alenda C, Llor X, Xicola RM, Jover R, Payá A, Bessa X, Balaguer F, Cubiella J, Argüello L, Morillas JD, Bujanda L; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Rodríguez-Moranta F, et al. Among authors: paya a. Am J Gastroenterol. 2006 May;101(5):1104-11. doi: 10.1111/j.1572-0241.2006.00522.x. Am J Gastroenterol. 2006. PMID: 16696788
131 results